Advertisement
Table 4 Estimates of key quantities characterizing the performance of the proposed two test workflow when 1-year or 3-year occurrences of hazardous events (HE) are taken into account along with 6-month angiographic restenosis results
| Estimated quantity | 1- year HE | 3- years HE | ||
|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | |
| \( \widehat{P}\left(\mathrm{sBMS}\right) \) | 9.7 | 3.6 – 18.0 | 5.0 | 2.6 – 9.5 |
| \( \widehat{P}\left(\mathrm{sDES}\right) \) | 81.8 | 74.3 – 87.5 | 85.3 | 81.4 – 87.7 |
| \( \widehat{P}\left(\mathrm{sCABG}\right) \) | 8.5 | 7.5 – 9.0 | 9.6 | 7.8 – 10.6 |
| \( \widehat{P}\left(\mathrm{Restenosis}\left|\mathrm{sBMS}\right.\right) \) | 0.1 | 0.0 – 0.0 | 0.0 | 0.0 – 0.0 |
| \( \tilde{P}\left(\mathrm{Restenosis}\left|\mathrm{sDES}\right.\right) \) | 7.6 | 6.7 – 7.9 | 7.0 | 6.1 – 7.5 |
| \( \widehat{P}\left(\mathrm{Restenosis}\right) \) | 6.4 | 5.5 – 6.9 | 6.2 | 5.3 – 6.6 |
| \( \tilde{P}\left(\mathrm{Hazard}\left|\mathrm{sBMS}\right.\right) \) | 0.0 | 0.0 – 0.0 | 1.5 | 0.0 – 16.7 |
| \( \widehat{P}\left(\mathrm{Hazard}\left|\mathrm{sDES}\right.\right) \) | 3.2 | 2.1 – 3.5 | 8.2 | 7.2 – 9.5 |
| \( \widehat{P}\left(\mathrm{Hazard}\right) \) | 3.3 | 2.5 – 3.8 | 7.9 | 6.9 – 9.5 |
| Baseline estimate for P(Adverse effect) | 14.1 | 12.6 – 14.5 | 18.8 | 17.6 – 19.6 |
| Proposed estimate for P(Adverse effect) | 9.7 | 8.3 – 10.6 | 14.1 | 12.4 – 15.6 |
| ΔP(Adverse effect) | 4.4 | 3.5 – 5.4 | 4.7 | 3.4 – 5.5 |
